SecBot SecBot
PRESS-RELEASE ·Filed May 6, 2026

ASND

Ascendis Pharma
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The data is confirmatory and unlikely to materially move the stock given prior FDA approval. Monitor EU regulatory decision in Q4 2026 and early sales trends of YUVIWEL. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$246.14
T+0 close · May 6, 2026 · via day close
Latest settled
−1.09%
T+60 · $243.45
Vs SPY
−4.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $246.14entry
  2. T+1 · 6mo ago 0.00%α −0.83% · $246.14
  3. T+5 · 6mo ago −1.04%α −2.54% · $243.58
  4. T+20 · 5mo ago −11.92%α −15.06% · $216.79
  5. T+60 · 3mo ago −1.09%α −4.93% · $243.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma reported positive subgroup data from the ApproaCH trial of TransCon CNP (navepegritide) in achondroplasia. Children ≥5 years showed significantly greater annualized growth velocity vs placebo at Week 52 (+1.78 cm/year, p<0.0001) with sustained improvements through Week 104. The drug was already FDA-approved in February 2026; the data strengthens the profile and supports ongoing EU regulatory review.

Key Facts

  • Subgroup of children ≥5 years at enrollment: AGV treatment difference +1.78 cm/year vs placebo at Week 52 (p<0.0001)
  • Sustained growth improvements observed through Week 104
  • Safety profile consistent with overall population; no symptomatic hypotension or bone age acceleration
  • TransCon CNP (YUVIWEL) FDA-approved February 2026 for achondroplasia in patients ≥2 years
  • EU regulatory decision expected Q4 2026

Financial Impact

No direct financial impact from this data; may support commercial uptake and EU approval

Risk Factors

  • Potential delays or negative outcome in EU regulatory review
  • Competition from other achondroplasia therapies (e.g., vosoritide)
  • Reimbursement and market access challenges

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3289301

Track record

41 reports on ASND

Performance horizon

14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 27 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $267.07 Now $271.73 +1.74% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026